Venus Remedies’ arm bags MA approval to sell Meropenem in France

Venus Pharma GmbH, a subsidiary of Venus Remedies, has made big strides in the global market by bagging marketing authorisation (MA) approval from France for Meropenem, a generic broad spectrum antibiotic injectable. It has signed a non-exclusive marketing rights deal with generic giant Mylan to sell Meropenem in France world's fifth largest pharmaceutical market with a market share of 3.8%.

Driven by its MA grants, Venus is all set to grab the maximum share in the $270-million Meropenem market in the EU in the near future. Meropenem is an off-patented generic broad spectrum anti-bacterial agent of carbapenem family, which fights diseases with a broad range of serious infections caused by single or multiple susceptible bacteria in both adults and children.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.